Please note that the ANZCTR website will be unavailable from 3:00-3:30pm this Thursday the 25th of October. At this time the IPD sharing statement and summary results sections will be added to the ANZCTR form in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Trial ID
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia
Scientific title
Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia (AML) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Study type
Description of intervention(s) / exposure
Treatment: Drugs - CSL360

Experimental: I - Treatment with CSL360

Treatment: Drugs: CSL360
Weekly IV Infusion. Dose escalation study.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Adverse events, pharmacokinetics
Timepoint [1] 0 0
September 2009
Secondary outcome [1] 0 0
Maximum tolerated dose
Timepoint [1] 0 0
September 2009
Secondary outcome [2] 0 0
Partial, complete and overall response
Timepoint [2] 0 0
September 2009
Secondary outcome [3] 0 0
Biological activity
Timepoint [3] 0 0
September 2009

Key inclusion criteria
- Clinical diagnosis of acute myeloid leukemia

- Recent bone marrow biopsy

- Prior treatment or medically unfit for standard therapy
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Peripheral blood blast count > 30 x 109/L, or rapidly progressive AML

- Previous solid organ transplant

- Active GvHD or immunosuppression

- Concurrent treatment with other anti-cancer therapy

- Active infections

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Brisbane
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Institute of Medical & Veterinary Science - Adelaide
Recruitment hospital [5] 0 0
Peter MacCallum Cancer Institute - Melbourne
Recruitment hospital [6] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4029 - Brisbane
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
3002 - Melbourne
Recruitment postcode(s) [6] 0 0
3052 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
CSL Limited

Ethics approval
Ethics application status

Brief summary
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of the myeloid line of white blood cells and impaired production
of normal blood cells. If untreated, patients die of infection or bleeding usually in a
matter of weeks. CSL360 is a neutralising monoclonal antibody which is believed to target the
cells that are thought to drive AML but that are not effectively killed by standard
treatment. The aims of the study are to determine a biologically active dose of CSL360 and
generate understanding of a rational schedule of administration for future studies.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Andrew Roberts, Dr
Address 0 0
Melbourne Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries